The research team at ARC is currently managing several different clinical studies. Are you interested in a particular study opportunity? Information about current study opportunities currently enrolling patients can be found below. Both ARC patients and non-ARC patients who fit the trial eligibility requirements are welcome.
A phase III trial to assess the efficacy, safety, and tolerability of zibotentan combined with dapagliflozin, compared to dapagliflozin alone, in participants with chronic kidney disease and high proteinuria.